Drug Profile


Alternative Names: HPMA copolymer doxorubicin PK2; Liver-targeted doxorubicin-HPMA conjugate

Latest Information Update: 02 Sep 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action Asialoglycoprotein receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Liver cancer

Most Recent Events

  • 28 Sep 1999 Phase-I clinical trials for Liver cancer in United Kingdom (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top